Back to Search Start Over

Physicochemical considerations in the preparation of amorphous ritonavir–poly(ethylene glycol) 8000 solid dispersions

Authors :
Law, Devalina
Krill, Steven L.
Schmitt, Eric A.
Fort, James J.
Qiu, Yihong
Wang, Weili
Porter, William R.
Source :
Journal of Pharmaceutical Sciences; August 2001, Vol. 90 Issue: 8 p1015-1025, 11p
Publication Year :
2001

Abstract

A systematic study of the properties of ritonavir and the influence of polyethylene glycol 8000 (PEG) on ritonavir revealed that amorphous ritonavir dispersions in PEG would have an improved dissolution profile and could exhibit long-term stability. Ritonavir, a human immunodeficiency virus (HIV) protease inhibitor, is highly lipophilic [distribution coefficient (log D)= 4.3, 25°C, pH 6.8], poorly water soluble (400 μg/mL in 0.1 N HCl, 1 μg/mL at pH 6.8, 37°C), and exhibits an exceedingly slow dissolution rate (0.03 mg/cm<SUP>2</SUP>-min in 0.1 N HCl at 37°C). These properties indicated that a solid dispersion containing ritonavir might be useful for overcoming problems associated with slow dissolution. In addition, ritonavir is a good glass former [glass-transition temperature (T<INF>g</INF>)/melting point (T<INF>m</INF>) > 0.7]. Amorphous ritonavir has an apparent solubility of 4 mg/mL in 0.1 N HCl at 37°C and shows reasonable stability at 25°C. Amorphous ritonavir, therefore, has properties desirable for preparing a solid dispersion containing this phase. Since PEG, a commonly used polymer, improved the aqueous solubility of crystalline ritonavir, it was expected to have a positive influence on the dissolution rate of ritonavir. Moreover, PEG was found to have negligible plasticizing effect on amorphous ritonavir, which was beneficial for the stability of the dispersion. Finally, solid dispersions of amorphous ritonavir in PEG were prepared, and these dispersions had improved in vitro dissolution rate and were physically stable for > 1.5 years at 25°C when protected from moisture. The performance of this solid dispersion has been attributed to the physicochemical properties of amorphous ritonavir. © 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:1015–1025, 2001

Details

Language :
English
ISSN :
00223549 and 15206017
Volume :
90
Issue :
8
Database :
Supplemental Index
Journal :
Journal of Pharmaceutical Sciences
Publication Type :
Periodical
Accession number :
ejs2086283
Full Text :
https://doi.org/10.1002/jps.1054